Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07598721 · ClinicalTrials.gov registry record · NA
Ambient AI Clinical Trial
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 139
- Enrollment target
NCT07598721: Completed NA study, sponsored by University of Washington.
NCT07598721 is a NA study that has completed, run by University of Washington. The registered enrollment target is 139 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07598721, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 139 participants
- Enrollment target
Study Summary
This is a single-site pragmatic randomized control trial studying the effect of ambient artificial intelligence (AI) scribes on the delivery of medical care to patients in the ambulatory setting. The study will last 150 days and include up to 65 providers in the intervention group. Providers will be recruited from three medical specialties, including primary care, oncology, and urology. The study will enroll providers and randomize them to an intervention group (access to the ambient AI scribe product) or a control group (routine patient care). Providers will be evaluated for burnout and task load measures through digital surveys at the beginning, middle, and end of the study. Provider electronic health record (EHR) usage data will also be evaluated for time spent documenting, time spent after hours on days with scheduled clinical care, and time between the start of the clinical encounter and signing it.
Primary Outcome
Change in professional fulfillment and burnout, measured using the Professional Fulfillment Index (PFI), a validated 16-item self-report questionnaire. The instrument comprises three subscales: Professional Fulfillment (6 items), Work Exhaustion (4 items), and Interpersonal Disengagement (6 items). Items are rated on a 5-point Likert scale (0 = "Not at all true" / "Not at all" to 4 = "Completely true" / "Extremely"). Subscale scores are calculated as the mean of constituent items. Unit of measur
Interventions
- OTHER Use of Ambient AI scribe tool on participant's mobile device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2025-07-04 |
| Phase | NA |
What the finished NCT07598721 record still lists
NCT07598721 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Use of Ambient AI scribe tool on participant's mobile device is the first listed.
NCT07598721 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07598721 about?
NCT07598721 is a clinical study titled "Ambient AI Clinical Trial". This is a single-site pragmatic randomized control trial studying the effect of ambient artificial intelligence (AI) scribes on the delivery of medical care to patients in the ambulatory setting. The study will last 150 days and include up to 65 providers in the intervention group. Providers will be...
What is the current status of trial NCT07598721?
This trial is currently completed. It is a NA study. The enrollment target is 139 participants. The study started on 2024-12-19. Estimated completion is 2025-07-04.
What interventions are being tested in trial NCT07598721?
The interventions under investigation include: Use of Ambient AI scribe tool on participant's mobile device (OTHER).
Who is sponsoring clinical trial NCT07598721?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07598721's enrollment target sits among peer trials
139 720th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI